Neopterin is released by macrophages during inflammatory responses leading to cytokine storms, a hall-mark of SARS-CoV-2 infection. Hence, a case-control design study was conducted to analyze the association of serum neopterin levels with COVID-19. A total of 610 individuals participated of which 374 were hospitalized COVID-19 patients and 256 were healthy donors. Hospitalized COVID-19 patients were all symptomatic and displayed a large spectrum of comorbidities.
The patients were followed until disease resolution or death. Upon comparing the serum neopterin levels of COVID-19 patients with the healthy individuals it was found that COVID-19 patients had significantly elevated neopterin levels.
The concentration of neopterin in COVID-19 patients at admission was 56 nM whereas the neopterin concentration in healthy individuals was the only 9.5nM. Moreover, systemic neopterin levels above 53nM distinguished between non-survivors and survivors with 64% specificity and 100% sensitivity. Furthermore, it was also assessed that neopterin levels were not associated with variables such as country, hypertension, and in particular age which can appear to be risk factors for non-survivals.
Thus, our study shows that neoprotein can serve as a predictive biomarker for mortality, post-SARS-CoV-2 infection. Measurement of neopterin concentration in body fluids is easily available in routine laboratories and hence can be assessed to a large number of potential patients. High neopterin levels are a hallmark of severe Covid-19 infection and should be implemented as a rapid and easy clinical tool to guide the allocation of healthcare facilities during pandemics and aid in the triage of infected patients for special medical care.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here